May 2024 in “Journal of molecular structure” A new compound, 3a, effectively fights prostate cancer better than finasteride.
23 citations
,
December 2013 in “Molecular cancer therapeutics” Breast cancer treatments work better with AR activation, improving results and reducing side effects.
2 citations
,
November 2025 in “British Journal of Pharmacology” Daprodustat, combined with PAβN, could be a new antibacterial treatment.
18 citations
,
November 2012 in “Current opinion in urology” Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.
February 2023 in “European Journal of Medical Research” Certain existing drugs, like glycopyrronium and botulinum toxin type A, may help treat excessive sweating.
14 citations
,
March 2017 in “Brain research” Progesterone and its byproducts control a specific receptor in the brain independently of progesterone receptors, affecting conditions related to the menstrual cycle.
64 citations
,
March 2008 in “Neuropsychopharmacology” February 2026 in “The Journal of Sexual Medicine” GnRH agonists can help manage recurrent priapism in sickle cell patients, but long-term safety is unclear.
3 citations
,
January 2023 in “Clinical cancer investigation journal” Some cannabinoid derivatives may be more effective than current drugs at targeting proteins relevant to prostate cancer treatment.
8 citations
,
October 2016 in “Journal of Investigative Dermatology” MR antagonists may improve skin health and wound healing, especially in aging.
January 2004 in “Drug Development and Industrial Pharmacy” GI197111X is best dissolved in Capmul MCM for trials.
45 citations
,
April 2021 in “Current Treatment Options in Oncology” ADT for prostate cancer may harm the heart, but GnRH antagonists might be safer.
1 citations
,
November 1975 in “PubMed” GRF is not safe for tubal occlusion.
12 citations
,
April 1995 in “Journal of Medicinal Chemistry” The new compounds moderately block a specific enzyme and strongly counteract a male hormone, suggesting potential for treating certain male-related health conditions.
12 citations
,
June 2001 in “Bioorganic & Medicinal Chemistry” Changing the C-ring structure in certain compounds can make them better at blocking a specific human enzyme.
April 2026 in “Frontiers in Cell and Developmental Biology” GPCRs are vital for wound healing by affecting cell growth and immune response.
1 citations
,
February 2023 in “Russian Journal of Bioorganic Chemistry” The new compound may be a safer alternative to finasteride for prostate protection.
May 2024 in “Scientific African” Three natural compounds from Ghanaian plants may help treat BPH and alopecia.
19 citations
,
September 2013 in “Psychoneuroendocrinology” Blocking CYP17A1 enzyme may help improve certain brain function issues related to dopamine.
7 citations
,
January 2025 in “Journal of Experimental & Clinical Cancer Research” PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.
17 citations
,
August 2007 in “Bioorganic & Medicinal Chemistry Letters” A compound made by Pfizer can potentially stimulate hair growth and reduce oil production, making it a good candidate for topical use.
6 citations
,
September 2015 in “Journal of Medicinal Chemistry” The document confirms the structures of major metabolites of the CRTh2 antagonist Setipiprant and identifies minor metabolites.
16 citations
,
December 2012 in “Bioinformation” Curcumin, EGCG, barringtozenol, and finasteride are effective VEGFR inhibitors.
November 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Different types of PPARγ are found in varying amounts in human skin and its parts, which could affect how skin treatments work.
53 citations
,
June 1993 in “Proceedings of the National Academy of Sciences of the United States of America” LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.
September 2020 in “Current Enzyme Inhibition” Three compounds were found to inhibit a prostate disease-related enzyme and reduce prostate size more effectively than the current treatment, suggesting they could be used for treating benign prostatic hyperplasia.
1 citations
,
October 2009 in “Current psychiatry” Choose treatments for sex offenders based on individual needs, using hormonal and nonhormonal options to reduce sexual drive.
3 citations
,
June 2018 in “Bioorganic & medicinal chemistry” Compounds 4, 4b, and 4c effectively inhibit an enzyme linked to testosterone conversion without significant toxicity.
25 citations
,
December 2001 in “Expert Opinion on Pharmacotherapy” Potassium channel openers show promise for treating heart disease and other conditions, but more research is needed to fully understand their effects and safety.
5 citations
,
January 2022 in “Clinical cancer investigation journal” Certain Dibenzo derivatives may help treat prostate cancer.